Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
With an estimated 33.2 million people in the world infected with the virus, human immunodeficiency virus (HIV) is a major medical problem.
The purpose of this study is to evaluate the safety of a new medication (GSK1349572) in HIV infected individuals who have never taken antiretroviral medications before. This study is also comparing the efficacy of GSK1349572 + epzicom to Atripla which is currently one of the medications used for HIV therapy.
Who may be Eligible
You may be eligible if you:
Are an HIV infected individual who is 18 years old or older
Have never taken HIV medications.
Have a viral load >1000 copies/mL
You are not pregnant or breastfeeding or planning on becoming pregnant during the term of the trial (96 weeks).
Not have a positive HLA-B*5701 which is verified by your doctor
Have no active AIDS defining illness at your first study visit.
Have not received an HIV-1 vaccine in the past 90 days
Do not meet criteria of exclusion based on your routine lab results
Do not have a history of cancer in the past 5 years
Will not be treated for hepatitis C during the study term.
Have not received an experimental medication within 28 days